A study links the size of cysts associated with endometriosis with coexistent ovarian cancer.
A relationship between endometriosis and ovarian cancer has been acknowledged for more than a decade,1 but a new study that evaluates data collected from 800 patients over 10 years finds a connection between the likelihood of ovarian cancer and the duration of endometriosis and the size of the cysts associated with the disease.2
Endometriosis occurs when tissue that normally lines the uterine lining grows outside it, involving the ovaries, fallopian tubes and the pelvis. The disorder can cause extreme pain to women in their child-bearing years and interfere with conception. Treatments include surgery and taking hormone therapy.
A 2008 literature review by Nezhat et al found a prevalence of endometriosis in patients with epithelial ovarian cancer, “especially in endometrioid and clear cell types” at levels higher than the general population. Certain genetic alterations were found to be especially common, and endometriosis was linked to a “chronic inflammatory state leading to cytokine release.” The cytokines promote cell division, differentiation, and other processes that are similar to cancer growth. The review said much more work was needed to detail the link between endometriosis and ovarian cancer.1
A 2016 review reported that 80% of endometrosis-associated malignancies are found on the ovary, and that the condition is associated with “a remarkably high increase of ovarian cancer risk.” When these cancers occur, the patients tend to be younger, Krawczyk et al, reported.3
Now, a study in the International Journal of Gynaecology and Obstetrics2 tracked women from a tertiary care hospital whose surgery confirmed their diagnosis of endometriosis during the period from January 1, 2010, and December 31, 2019. The study was done to determine how often patients with endometriosis also had cancer; patient details were obtained from electronic records, and investigators conducted analysis to determine which independent risk factors were associated with cancers.2
Of the 800 patients, 104 (13%) had a coexistent malignancy, including 50 cases of ovarian cancer (6.2%); 33 cases of endometrial cancer (4.1%); 7 cases of patients who had both ovarian and endometrial cancer (0.9%); and 14 cases of breast cancer (1.8%).
Cancer was associated with increasing age, for an odds ratio (OR) of 1.13 (95% CI, 1.09-1.16); higher levels of cancer antigen 125 (OR, 1.002; 95% CI, 1.001-1.005); postmenopausal status (OR 6.2; 95% CI, 2.0-19.2); and having endometriosis more than 5 years (OR, 4.7; 95% CI 2.5-9.0). Having endometriomas larger than 8 cm was predictive than of coexistent malignancy.
References
1. Nezhat F, Datta S, Hanson V, Pejovic T, Nezhat C, Nezhat C. The relationship of endometriosis and ovarian malignancy: a review. Fertility and Sterility. 2008;90(5):1550-1570.
2. Dahiya A, Sebastian A, Thomas A, George R, Thomas V, Peedicayil A. Endometriosis and malignancy: the intiriguing relationship. Int J Gynaecol Obstet. Published online January 8, 2021. doi: 10.1002/ijgo.13585.
3. Krawczyk N, Banys-Paluchowski M, Schmidt D, Ulrich U, Fehm T. Endometriosis-associated malignancy. Geburtshilfe Frauenheilkd. 2016;76(2):176-181. doi: 10.1055/s-0035-1558239
AI Outperforms Traditional Methods in Predicting Ovarian Cancer Surgery Outcomes
January 19th 2025Artificial intelligence (AI) models, particularly artificial neural networks and machine learning, outperform traditional methods in predicting post–complete cytoreduction outcomes in patients with ovarian cancer, including overall survival, no residual disease, and postoperative complications.
Read More
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Niraparib Improves Outcomes in Patients With Stage III EOC, No Visible Residual Disease
January 14th 2025Patients with stage III epithelial ovarian cancer (EOC) and no visible residual disease after primary cytoreductive surgery had significantly longer real-world progression-free survival and time to next treatment when treated with first-line maintenance niraparib compared with those with higher-risk disease.
Read More
Nomogram Predicts Overall Survival in Patients With Ovarian Cancer, Liver Metastases
January 9th 2025Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian cancer and liver metastases (OCLM), outperforming an external model in stability and accuracy.
Read More
Global Trends in Ovarian Cancer Incidence Highlight Regional, Histological Variations
January 7th 2025Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, influenced by genetic, reproductive, and socioeconomic factors.
Read More
Top 5 Most-Read Ovarian Cancer Content of 2024
December 29th 2024The top 5 ovarian cancer articles of 2024 covered topics such as the impact of air pollution on ovarian cancer risk, treatment strategies for patients with liver metastases, and the benefits of early diagnosis through symptom-triggered testing.
Read More